Overview

Platelet Rich Plasma Market is estimated to value over USD 900 million by 2028 end with a CAGR of over 12.5% during the forecast period 2022 to 2028.

Blood is largely a liquid (called plasma), but it also contains small solid components (red cells, white cells, and platelets). One of the most important functions of platelets is to clot blood. As well as proteins called growth factors, platelets also contain hundreds of other substances that are crucial to the healing process.
PRP is plasma containing many more platelets than blood typically contains. Growth factors are concentrated in higher concentrations in platelets than in the usual concentrations. The first step in developing a PRP preparation involves obtaining blood from a patient. A process called centrifugation separates the platelets from other blood cells and increases their concentration. Following this, the platelets will be injected into the injured area.

At least seven growth factors are found in platelet rich plasma (PRP). It can be used to treat chronic tendon injuries, acute ligament and muscle injuries, surgery, knee arthritis, fractures, and discomfort, among other conditions. The usage of PRP in orthopaedics is predicted to rise throughout the projection period. Acute sports injuries, such as muscular strains, are increasingly being treated using PRP. PRP is becoming more popular, however its real usefulness has yet to be determined. As a result, PRP is frequently utilised in surgery to repair injured knee ligaments like the anterior cruciate ligament (ACL). PRP aids in the rapid healing of tissue following surgical treatments.

Several research studies are under underway to determine the efficacy of PRP in different therapy areas, such as herniated discs and hair loss. Because of its increased availability and capacity to speed up recovery, PRP is now frequently used in a variety of therapeutic fields. Additionally, this treatment has the potential to cut the financial expenditures of typical medical treatments, while it cannot completely replace many vital traditional therapies.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Platelet Rich Plasma Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Platelet Rich Plasma Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Platelet Rich Plasma Market:

• T-Biotechnology (T-LAB)
• Arthrex, Inc
• Terumo BCT, Inc
• EmCyte Corporation
• DePuy Synthes
• Zimmer Biomet
• Stryker
• Glofinn Oy
• DR. PRP America, LLC.      
(Note: The list of the major players will be updated with the latest market scenario and trends)

Platelet Rich Plasma Market Segmentation:

By Type

• Pure Platelet-rich Plasma
• Leukocyte Platelet-rich Plasma
• Pure Platelet-rich Fibrin
• Leukocyte Platelet-rich Fibrin

By Origin

• Autologous Platelet-rich Plasma
• Allogeneic Platelet-rich Plasma
• Homologus Platelet-rich Plasma

By Application
• Cosmetic Surgery
  o Skin Care
  o Hair Care
• Orthopedic Surgery
• Ophthalmic Surgery
• Dentistry
• Cardiac Surgery
• Neurosurgery
• Other Indications

By Indication Stages
• Cosmetic Surgery
  o Skin Care - Stage I, Stage II, Stage III, Stage IV
    • Skin Ulcers
      o Diabetic Foot Ulcer - Stage I, Stage II, Stage III, Stage IV
      o Pressure Ulcer – Stage I, Stage II, Stage III, Stage IV
      o Venous Insufficiency - Stage I, Stage II, Stage III
      o Atherosclerosis – Stage I, Stage II, Stage III
  o Hair Care
    • Stage I
    • Stage II
    • Stage III
    • Stage IV
• Orthopedic Surgery
  o Stage I
  o Stage II
  o Stage III
  o Stage IV
• Ophthalmic Surgery
  o Stage I
  o Stage II 
  o Stage III
  o Stage IV
• Dentistry
  o Stage I
  o Stage II 
  o Stage III
  o Stage IV
• Cardiac Surgery
  o Stage I
  o Stage II 
  o Stage III
  o Stage IV
• Neurosurgery
  o Stage I
  o Stage II 
  o Stage III
  o Stage IV

By End-User

• Physician's office/Private Practice 
• Hospitals            
• Orthopedic Clinics 
• Ophthalmic Clinics
• Cosmetic/Dermatology/Trichology Clinics 
• Academic & Research Institutes

By Region
•    North America
•    Latin America
•    Europe
•    Asia-Pacific
•    Middle East and Africa

Platelet Rich Plasma Market Sample Video:

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global platelet rich plasma market by type, by origin, by application, by indication stages, by end user and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Platelet Rich Plasma Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Platelet Rich Plasma Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Platelet Rich Plasma Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Platelet Rich Plasma Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Pure Platelet-rich Plasma
   7.2. Leukocyte Platelet-rich Plasma
   7.3. Pure Platelet-rich Fibrin
   7.4. Leukocyte Platelet-rich Fibrin

8. Platelet Rich Plasma Market, By Origin Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Autologous Platelet-rich Plasma
   8.2. Allogeneic Platelet-rich Plasma
   8.3. Homologous Platelet-rich Plasma

9. Platelet Rich Plasma Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Cosmetic Surgery
        9.1.1. Skin Care
        9.1.2. Hair Care
   9.2. Orthopedic Surgery
   9.3. Ophthalmic Surgery
   9.4. Dentistry
   9.5. Cardiac Surgery
   9.6. Neurosurgery
   9.7. Other Indications

10. Platelet Rich Plasma Market, By Indication Stages Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Cosmetic Surgery
          10.1.1. Skin Care - Stage I, Stage II, Stage III, Stage IV
                  10.1.1.1. Skin Ulcers
                            10.1.1.1.1. Diabetic Foot Ulcer - Stage I, Stage II, Stage III, Stage IV
                            10.1.1.1.2. Pressure Ulcer – Stage I, Stage II, Stage III, Stage IV
                            10.1.1.1.3. Venous Insufficiency - Stage I, Stage II, Stage III
                            10.1.1.1.4. Atherosclerosis – Stage I, Stage II, Stage III
          10.1.2. Hair Care
                  10.1.2.1. Stage I
                  10.1.2.2. Stage II
                  10.1.2.3. Stage III
                  10.1.2.4. Stage IV
    10.2. Orthopedic Surgery
          10.2.1. Stage I
          10.2.2. Stage II
          10.2.3. Stage III
          10.2.4. Stage IV
    10.3. Ophthalmic Surgery
          10.3.1. Stage I
          10.3.2. Stage II 
          10.3.3. Stage III
          10.3.4. Stage IV
    10.4. Dentistry
          10.4.1. Stage I
          10.4.2. Stage II 
          10.4.3. Stage III
          10.4.4. Stage IV
    10.5. Cardiac Surgery
          10.5.1. Stage I
          10.5.2. Stage II 
          10.5.3. Stage III
          10.5.4. Stage IV
    10.6. Neurosurgery
          10.6.1. Stage I
          10.6.2. Stage II 
          10.6.3. Stage III
          10.6.4. Stage IV

11. Platelet Rich Plasma Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
    11.1. Physician's office/Private Practice 
    11.2. Hospitals            
    11.3. Orthopedic Clinics 
    11.4. Ophthalmic Clinics
    11.5. Cosmetic/Dermatology/Trichology Clinics 
    11.6. Academic & Research Institutes

12. North America Platelet Rich Plasma Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. U.S.A
          12.2.2. Canada
          12.2.3. Mexico
    12.3. Market Size (USD Million) Forecast for North America 2022-2028

13. Latin America Platelet Rich Plasma Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Brazil
          13.2.2. Venezuela
          13.2.3. Argentina
          13.2.4. Rest of Latin America
    13.3. Market Size (USD Million) Forecast for Latin America 2022-2028

14. Europe Platelet Rich Plasma Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Germany
          14.2.2. U.K         
          14.2.3. France
          14.2.4. Italy
          14.2.5. Spain
          14.2.6. Russia
          14.2.7. Poland
          14.2.8. Rest of Europe
    14.3. Market Size (USD Million) Forecast for Europe 2022-2028

15. Asia Pacific Platelet Rich Plasma Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. Japan
          15.2.2. China
          15.2.3. India
          15.2.4. Australia and New Zealand
          15.2.5. ASEAN
          15.2.6. Rest of Asia Pacific
    15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    16.1. Introduction
    16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          16.2.1. GCC
          16.2.2. Israel
          16.2.3. South Africa
          16.2.4. Rest of MEA
    16.3. Market Size (USD Million) Forecast for MEA 2022-2028

17. Market Share Analysis and Competitive Landscape   
    17.1. Global Landscape - Key Players, Revenue and Presence
    17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    17.3. Global Emerging Companies
    17.4. North America - Market Share Analysis and Key Regional Players
    17.5. Europe - Market Share Analysis and Key Regional Players
    17.6. Asia Pacific - Market Share Analysis and Key Regional Players
    17.7. Global Key Player - Growth Matrix

18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    18.1. T-Biotechnology (T-LAB)
          18.1.1. Company Overview
          18.1.2. Product Portfolio
          18.1.3. SWOT Analysis
          18.1.4. Financial Overview
          18.1.5. Strategic Overview       
    18.2. Arthrex, Inc.
          18.2.1. Company Overview
          18.2.2. Product Portfolio
          18.2.3. SWOT Analysis
          18.2.4. Financial Overview
          18.2.5. Strategic Overview
    18.3. Terumo BCT, Inc.
          18.3.1. Company Overview
          18.3.2. Product Portfolio
          18.3.3. SWOT Analysis
          18.3.4. Financial Overview
          18.3.5. Strategic Overview 
    18.4. EmCyte Corporation
          18.4.1. Company Overview
          18.4.2. Product Portfolio
          18.4.3. SWOT Analysis
          18.4.4. Financial Overview
          18.4.5. Strategic Overview
    18.5. DePuy Synthes
          18.5.1. Company Overview
          18.5.2. Product Portfolio
          18.5.3. SWOT Analysis
          18.5.4. Financial Overview
          18.5.5. Strategic Overview   
    18.6. Zimmer Biomet
          18.6.1. Company Overview
          18.6.2. Product Portfolio
          18.6.3. SWOT Analysis
          18.6.4. Financial Overview
          18.6.5. Strategic Overview
    18.7. Stryker
          18.7.1. Company Overview
          18.7.2. Product Portfolio
          18.7.3. SWOT Analysis
          18.7.4. Financial Overview
          18.7.5. Strategic Overview  
    18.8. Glofinn Oy
          18.8.1. Company Overview
          18.8.2. Product Portfolio
          18.8.3. SWOT Analysis
          18.8.4. Financial Overview
          18.8.5. Strategic Overview
    18.9. DR. PRP AMERICA LLC
          18.9.1. Company Overview
          18.9.2. Product Portfolio
          18.9.3. SWOT Analysis
          18.9.4. Financial Overview
          18.9.5. Strategic Overview      
    18.10.Johnson & Johnson
          18.10.1. Company Overview
          18.10.2. Product Portfolio
          18.10.3. SWOT Analysis
          18.10.4. Financial Overview
          18.10.5. Strategic Overview
    18.11. Exactech, Inc
          18.11.1. Company Overview
          18.11.2. Product Portfolio
          18.11.3. SWOT Analysis
          18.11.4. Financial Overview
          18.11.5. Strategic Overview 
    18.12. Biotest Aktiengesellschaft
          18.12.1. Company Overview
          18.12.2. Product Portfolio
          18.12.3. SWOT Analysis
          18.12.4. Financial Overview
          18.12.5. Strategic Overview   
    18.13. CSL Limited
          18.13.1. Company Overview
          18.13.2. Product Portfolio
          18.13.3. SWOT Analysis
          18.13.4. Financial Overview
          18.13.5. Strategic Overview

19. Pre and Post COVID-19 Impact
    19.1. Positive influence on the healthcare industry
    19.2. The financial disruption of the manufacturing sector
    19.3. Impact of COVID-19 on emerging companies
    19.4. Significant mandates in the healthcare regulations initiated by administrations
    19.5. The overall economic slowdown of the developing and developed nations

20. FutureWise SME Key Takeaway Points for Client

Tables

Figures